Table 3:

Baseline HCV treatment regimen

Regimen	Treatment group, no. (%)
	CT participants (n = 259 )	Non-CT participants (n = 170)*
Daclatasvir	2 (0.8)	0
Elbasvir–grazoprevir	63 (24.3)	57 (33.5)
Ledipasvir–sofosbuvir	22 (8.5)	5 (2.9)
Sofosbuvir	2 (0.8)	2 (1.2)
Sofosbuvir–velpatasvir	165 (63.7)	98 (57.6)
Glecaprevir–pibrentasvir	2 (0.8)	4 (2.4)
Sofosbuvir–velpatasvir–voxilaprevir	3 (1.2)	5 (2.9)

Note: Patients may have reported >1 baseline HCV treatment (combination treatment regimen)

* Patients could have received a combination of DAAs

HCV = Hepatitis C virus; CT = Core transmitter